We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

KYORIN Pharmaceutical Co.,Ltd. (JP:4569) has released an update. KYORIN Pharmaceutical Co., Ltd. has signed a licensing agreement with Bayer AG to ...

An investigation conducted by Canada’s National Observer finds that Bayer colluded with Canadian regulators to obstruct a ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

The shift from PVC to PET, while helping the company meet its sustainability goals, was met with challenges, including ...

UBS analyst Geoff Haire maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The company’s shares ...

Bayer is breaking into the irritable bowel syndrome (IBS) therapy market with the acquisition of HiDoc Technologies, which ...

Bayer Leverkusen have gone the entire calendar year unbeaten away from home in Germany, becoming the second team to do so.

Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

Bayer announced the successful completion of its fall employee engagement campaign with America’s Grow-a-Row (AGAR), a New ...